These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2204244)

  • 21. Pathogenesis, genetics of virulence, and immunity in Shigellosis.
    Formal SB; Kapfer C; Hale TL
    Kansenshogaku Zasshi; 1988 Mar; 62 Suppl():329-42. PubMed ID: 3138359
    [No Abstract]   [Full Text] [Related]  

  • 22. Immunization with Shigella dysenteriae type 1: evaluation of antitoxic immunity in prevention of experimental disease in rhesus monkeys (Macaca mulatta).
    McIver J; Grady GF; Formal SB
    J Infect Dis; 1977 Sep; 136(3):416-21. PubMed ID: 409782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection.
    DuPont HL; Hornick RB; Snyder MJ; Libonati JP; Formal SB; Gangarosa EJ
    J Infect Dis; 1972 Jan; 125(1):12-6. PubMed ID: 4550416
    [No Abstract]   [Full Text] [Related]  

  • 24. Recent progress towards development of a Shigella vaccine.
    Camacho AI; Irache JM; Gamazo C
    Expert Rev Vaccines; 2013 Jan; 12(1):43-55. PubMed ID: 23256738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies on vaccination against bacillary dysentery. 4. Oral immunization with live monotypic and combined vaccines.
    Mel DM; Arsić BL; Nikolić BD; Radovanić ML
    Bull World Health Organ; 1968; 39(3):375-80. PubMed ID: 5303905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Shigellosis in custodial institutions. II. Clinical, immunologic and bacteriologic response of institutionalized children to oral attenuated shigella vaccines.
    Levine MM; Dupont HL; Gangarosa EJ; Hornick RB; Snyder MJ; Libonati JP; Glaser K; Formal SB
    Am J Epidemiol; 1972 Jul; 96(1):40-9. PubMed ID: 4557072
    [No Abstract]   [Full Text] [Related]  

  • 27. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1.
    Pozsgay V; Chu C; Pannell L; Wolfe J; Robbins JB; Schneerson R
    Proc Natl Acad Sci U S A; 1999 Apr; 96(9):5194-7. PubMed ID: 10220442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experimental shigellosis in mice. II. Immunological responses to Shigella dysenteriae type 2 infection.
    COOPER GN; PILLOW JA
    Aust J Exp Biol Med Sci; 1959 Jun; 37():201-9. PubMed ID: 13811789
    [No Abstract]   [Full Text] [Related]  

  • 29. Vaccine research and development. New strategies for accelerating Shigella vaccine development.
    Wkly Epidemiol Rec; 1997 Mar; 72(11):73-9. PubMed ID: 9115858
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical & bacteriological profiles of shigellosis in Calcutta before & after an epidemic (1984-87).
    Dutta P; Dutta D; Bhattacharya SK; Sen D; Mitra U; Ghosh AR; Lahiri M; Deb BC
    Indian J Med Res; 1989 May; 89():132-7. PubMed ID: 2674001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prevention of bacillary dysentery using a live anti-dysentery vaccine in a group of neuropsychopathic children].
    Meitert T; Istrati G; Sulea IT; Baron E; Andronescu C; Gogulescu L; Templea C; Ianopol L; Galan L; Fleşeriu M; Onciu C; Bogos L; Lupovici R; Boghiţoiu G; Ohmt E; Popescu G; Mihailiuc I; Maftei S; Tapu T; Zebreniuc D
    Arch Roum Pathol Exp Microbiol; 1973 Mar; 32(1):35-44. PubMed ID: 4585403
    [No Abstract]   [Full Text] [Related]  

  • 32. Immunization of Mice with a Live Transconjugant Shigella Hybrid Strain Induced Th1 and Th17 Cell-Mediated Immune Responses and Confirmed Passive Protection Against Heterologous Shigellae.
    Nag D; Koley H; Sinha R; Mukherjee P; Sarkar C; Withey JH; Gachhui R
    Scand J Immunol; 2016 Feb; 83(2):92-101. PubMed ID: 26478541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Shigellosis in nonhuman primates: a review.
    Mulder JB
    Lab Anim Sci; 1971 Oct; 21(5):734-8. PubMed ID: 4329238
    [No Abstract]   [Full Text] [Related]  

  • 34. Prophylaxis of bacillary dysentery by liver vaccine Vadizen (Sh. flexneri T32-Istrati) in children collectivities in IS County.
    Oană C; Buzdugan T; Constantiniu S; Cismaru M; Alexandru D; Dunea C; Funiac A; Radu M; Grumăzescu C; Meitert T
    Arch Roum Pathol Exp Microbiol; 1984; 43(3-4):331-5. PubMed ID: 6400307
    [No Abstract]   [Full Text] [Related]  

  • 35. Future needs and directions for Shigella vaccines.
    Wkly Epidemiol Rec; 2006 Feb; 81(6):51-8. PubMed ID: 16673461
    [No Abstract]   [Full Text] [Related]  

  • 36. An update on Shigella vaccines.
    Ashkenazi S; Cohen D
    Isr J Med Sci; 1994; 30(5-6):495-7. PubMed ID: 8034510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Azithromycin prophylaxis prevents epidemic dysentery.
    Shanks GD; Ragama OB; Aleman GM; Andersen SL; Gordon DM
    Trans R Soc Trop Med Hyg; 1996; 90(3):316. PubMed ID: 8758091
    [No Abstract]   [Full Text] [Related]  

  • 38. Reduction of morbidity due to bacillary dysentery by live vaccine Vadizen (Sh. flexneri T32-Istrati) in children collectivities in BH County.
    Pop C; Cernea L; Ciortea A; Ianossy L; Kallay T; Lugoş A; Meitert T; Ciudin L; Pencu E
    Arch Roum Pathol Exp Microbiol; 1984; 43(3-4):351-6. PubMed ID: 6400310
    [No Abstract]   [Full Text] [Related]  

  • 39. Bacillary dysentery.
    Christie AB
    Br Med J; 1968 May; 2(5600):285-8. PubMed ID: 4869198
    [No Abstract]   [Full Text] [Related]  

  • 40. A cell-free polyvalent Shigella vaccine.
    Tamura JT
    J Infect Dis; 1967 Dec; 117(5):353-9. PubMed ID: 6078217
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.